MedTrace Logo

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

NCT02310269 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 152

Last updated 2024-10-15

Study results available
· View outcomes & findings →

Summary

This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in combination with other therapies will be monitored. For this study, each enrolled patient will be followed up for 3 years after enrollment. Patients who permanently discontinue pasireotide s.c. prior to completing the 3-year observation period will be followed up for 3 months after the last dose of pasireotide s.c.

Conditions

  • Cushings Disease

Interventions

DRUG

Pasireotide

Sponsors & Collaborators

  • RECORDATI GROUP

    lead INDUSTRY

Principal Investigators

  • Mario MALDONADO, MD · Recordati AG

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-28
Primary Completion
2023-07-10
Completion
2023-07-10

Countries

  • United States
  • Canada
  • Colombia
  • France
  • Germany
  • Israel
  • Italy
  • Lebanon
  • Netherlands
  • Romania
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02310269 on ClinicalTrials.gov